Navigation Links
Santaris Pharma Presents Positive Clinical Data on SPC2996 in,Chronic Lymphocytic Leukaemia

First RNA Antagonist Medicine to Be Tested in Patients Reduces Severity of Adult Leukaemia

Copenhagen, 6th June 2007 - Santaris Pharma, the Danish biopharmaceutical company, announced today that SPC2996, the Company's new RNA Antagonist of Bcl-2, has shown early evidence of efficacy in an initial Phase I/II clinical study in Chronic Lymphocytic Leukaemia (CLL). The results of the study were reported this week at the 2007 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois.

The clinical trial was conducted in patients with advanced CLL, the most common form of adult leukaemia, and involved 12 centres in France, Britain, Denmark, and the USA. Conclusions from the study were as follows.

*A reduction in the number of cancerous B-lymphocytes (white blood cells) and a beneficial effect on lymph nodes and overall tumour response was observed in patients given 6 repeated doses of drug at 4mg/kg/infusion over a two week period, with the effects on lymphocytes being seen within 24 hours of the first dose.

*A relationship between dose of SPC2996 and activity was observed in the study, with higher doses giving improved effects on lymphocyte counts, lymph nodes, time to progression and overall tumour response.

*SPC2996 treatment was associated with statistically significant reduction in mean Bcl-2 levels in white blood cells from CLL patients, supporting the intended mechanism of action of the drug.

Commenting on the results, Prof Bertrand Coiffier, from the Hospices Civils de Lyon, University of Lyon, France, the international coordinating investigator for the study, said:

"These results are early stage but promising. All patients came into this study with clinically progressing CLL. Despite this, patients receiving the drug at an effective level had rapid and sustained falls in circulating cancerous lymphocytes. There also appeared to be e
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:10/22/2014)... UNION CITY, Calif., Oct. 21, 2014 Abaxis, ... company manufacturing point-of-care blood analysis systems, today reported financial ... 2014. Second quarter overview: , Revenues ... quarter. , Diluted EPS of $0.24, up 33% ... , Service revenues from Abaxis Veterinary Reference Laboratories ...
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
Breaking Medicine Technology:Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
(Date:10/22/2014)... October 22, 2014 During the Western ... water supply runs dangerously low, Southern Oregon’s water is ... rivers, despite the lowest mountain snow pack on record ... summer and early autumn.* That was the observation of ... new book “Hiking Southern Oregon,” during an interview with ...
(Date:10/22/2014)... Healthcare professionals who are looking ... at home or on-the-go via laptops, tablets or ... new, premium Seminar-on-Demand CE courses. The new courses ... 2,000 hours of CE course offerings, allowing ... With such a diverse library, there’s something for ...
(Date:10/22/2014)... Although there are only 24 hours in a day, that doesn’t ... finding time within their busy schedules for exercise and fitness. Fortunately, ... to get in shape. Here are five ways you can reach ... Change Up Your Commute , Consider riding a bike or taking ... your daily routine. If you must use your car to get ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
Breaking Medicine News(10 mins):Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2
... study many Americans are affected by insomnia, not able to get ... to sleep aids that will act fast and put them to ... "cure," however, shouldn't be the first course of action, says a ... the market, doctors tend to rely upon them because samples are ...
... polio immunization campaign in Somalia, that will aim at vaccinating ... // ,The Head Honcho of WHO's Global Polio ... that the number of cases of polio are now beginning ... of the country which is a very difficult part of ...
... research team from Georgia Institute of Technology has developed ... (ATP) release and its role in cystic fibrosis. // ... and nano-electrodes to the tip of an atomic force ... monitor topography along with electrochemical activity at the cell ...
... down. The industry across the country is now facing a suicide ... the country, small farmers are scared due to low prices. // ... Rs 5 for one kg of chicken from Rs 1.80 and ... being forced to commit suicide. K Narayana Reddy, president, of Andhra ...
... study in Australia has found that babies born to women, ... birth weight and lower APGAR scores and are more likely ... women have a higher number of previous pregnancies, smoke more ... to the study in the April issue of Alcoholism: Clinical ...
... clot formation in both men and women according to a new ... cell testing in both sexes with 81 milligrams of acetyl salicylic ... platelets – the clot-forming cells. Clots in blood vessels of the ... while the drug's overall effects on blood cell function were the ...
Cached Medicine News:Health News:Sleep Aids Are Not The Best Option For Insomniacs 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 2Health News:New Multi-functional Sensing Tool To Investigate Cystic Fibrosis 3Health News:Use Of Alcohol During Pregnancy Affects Newborns 2Health News:Low-dose Aspirin Benefits Both Sexes 2Health News:Low-dose Aspirin Benefits Both Sexes 3Health News:Low-dose Aspirin Benefits Both Sexes 4
Hydragel K20 is Sebia's quality line of manual agarose gel electrophoresis products. Samples are applied utilizing the same patented applicator combs that is used for sample application on the HYDRAS...
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
Medicine Products: